Berberine

ID: berberine

Aliases: berberine HCl, BBR, Berberis alkaloid, berbeine

Type: compound

Route/form: oral supplement/nutraceutical; formulation and salt vary

Status: supplement_or_nutraceutical

Evidence level: human RCT

Best data tier: human controlled/review

Support scope: human, review/regulatory

Source types: human_rct, human_trial, meta_analysis, review, umbrella_review

Linked sources: 8

Broad outcomes: Cardiovascular / lipids / blood pressure, Fat loss / metabolic health, Muscle growth / performance / recovery, mTORC / autophagy / nutrient signaling

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• AMPK-centered metabolic signaling
• LDL receptor / PCSK9-adjacent lipid handling
• glucose and lipid metabolism
• AMPK-mTORC nutrient-sensing cross-talk

Optimization domains

• metabolic
• type 2 diabetes
• insulin resistance
• lipids
• body composition
• AMPK
• mTORC
• cardiometabolic

Research basis

• Human meta-analyses of randomized trials support modest glycemic and lipid-marker improvements, especially in type 2 diabetes and metabolic-disorder populations.
• A randomized obesity study adds body-composition and adipokine context, making it more relevant than a generic ?blood sugar supplement? entry.
• Mechanistic literature links berberine to AMPK/mTOR, LDLR/PCSK9-adjacent lipid handling, and broader metabolic signaling, which makes the rationale biologically coherent.

Limits, risks, and missing evidence

• Evidence quality is uneven, many trials are short and geographically concentrated, and effect sizes are not comparable to GLP-1/GIP agonists despite marketing nicknames.
• Low oral bioavailability, formulation differences, GI intolerance, pregnancy/infant safety issues, and drug-interaction potential complicate casual use.
• AMPK/mTORC signaling language should not be treated as proof of longevity, fat-loss, or performance benefit without outcome-specific human data.

Risk flags

• supplement quality variability
• GI tolerability
• drug interactions
• glucose lowering
• pregnancy infant caution
• not GLPI equivalent

Linked papers, labels, and reviews

1. Efficacy and Safety of Berberine Alone for Several Metabolic Disorders: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
   meta_analysis / pubmed_berberine_metabolic_disorders_meta_2021
   Meta-analysis of randomized trials across metabolic disorders; useful broad human anchor for glycemic, lipid, BMI, and safety signals.
2. Glucose-lowering effect of berberine on type 2 diabetes: A systematic review and meta-analysis
   meta_analysis / pubmed_berberine_t2d_glucose_meta_2022
   Type 2 diabetes-focused systematic review/meta-analysis; anchors berberine glucose-lowering claims to human RCT literature rather than ?natural Ozempic? marketing.
3. Comparative Effects of Gymnema sylvestre and Berberine on Adipokines, Body Composition, and Metabolic Parameters in Obese Patients: A Randomized Study
   human_rct / pubmed_berberine_obesity_rct_2024
   Randomized obesity study with body-composition, adipokine, and metabolic endpoints; useful direct body-composition context.
4. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins
   human_trial / pubmed_berberine_ldlr_2004
   Early human plus mechanistic source showing LDL-cholesterol reduction and LDL receptor upregulation mechanisms distinct from statins.
5. Molecular mechanisms, targets and clinical potential of berberine in regulating metabolism: a review focussing on databases and molecular docking studies
   review / pmc_berberine_metabolic_mechanisms_review_2024
   Mechanism review covering AMPK/mTOR, PCSK9/LDLR, SIRT/FOXO/SREBP, Nrf2, and other metabolic signaling pathways; useful but less direct than RCTs.
6. Berberine and health outcomes: An umbrella review
   umbrella_review / pubmed_berberine_health_outcomes_umbrella_2023
   Umbrella review grading meta-analytic evidence across berberine health outcomes; useful for separating promising signals from uneven study quality.
7. The effect of berberine supplementation on obesity parameters, inflammation and liver function enzymes: A systematic review and meta-analysis of randomized controlled trials
   meta_analysis / pubmed_berberine_obesity_inflammation_meta_2020
   RCT meta-analysis on berberine and anthropometrics, CRP, and liver enzymes; useful obesity/inflammation/liver-marker synthesis.
8. The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
   meta_analysis / pubmed_berberine_t2d_profiles_meta_2022
   RCT meta-analysis of berberine in type 2 diabetes; supports glycemic and metabolic-profile claims with study-quality caveats.